Multiple Myeloma Clinical Trial
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Summary
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Eligibility Criteria
Inclusion Criteria:
History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
Measurable multiple myeloma (MM)
Eastern Cooperative Oncology Group performance status of 0-1
Exclusion Criteria:
Condition that confounds the ability to interpret data from the study
Known active or history of central nervous system (CNS) involvement of MM
Note: Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 9 Locations for this study
Pittsburgh Pennsylvania, 15232, United States
How clear is this clinincal trial information?